Insider Buying Activity Uncovered - 7 Stocks On The Rise

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Energy Storage Trend Ignites Frenzy Over Vanadium Supply]( [See how investors could benefit from domestic vanadium discoveries.]( --------------------------------------------------------------- March 28, 2024 Editorial Insights Insider trading occurs when company executives or major shareholders trade stocks based on non-public information. Monitoring these trades provides insight into insiders' expectations for the company's future. For instance, significant purchases before public announcements may indicate anticipated positive news and a potential share price increase. Note: "Insider Buying" is legal stock purchasing by company directors or officers, distinct from illegal insider trading based on non-public information. It's not a crime when based on public information. Insiders, having unique insights, often buy shares when they believe the stock is undervalued. This report lists stocks recently identified with substantial insider buying. --------------------------------------------------------------- Sponsor Message [Bezos and Gates Invest in Search for Tech's Best-Kept Secret]( who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible. [Investor Alert: Discover a company flying-under-the-radar at the forefront of this megatrend.]( --------------------------------------------------------------- [ARS Pharmaceuticals, Inc.]( Ticker: [SPRY]( Recent Price: $11.20 Average Analyst Price Target: $19.00 (69.64%) Market Cap: $1.08B Role Transaction Description No. of Shares Amount Date Director, >10% Owner Informative Buy Non Open Market Buy 1,186,554 $13,289,410 2 Days Ago Recent Analyst Action: Roanna Ruiz, analyst at Leerink Partners, reiterates coverage on [ARS Pharmaceuticals, Inc. (SPRY)]( in the Healthcare sector with a Buy rating and a price target of $19 (1 week ago). Here are 3rd party ratings for [SPRY](: - TipRanks.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 36% (90 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Author of Get Rich with Dividends Is Giving Away His Ultimate Dividend Package FOR FREE!]( Click Here to Get Marc Lichtenfeld's Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 9% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. [For Free.]( --------------------------------------------------------------- [Summit Therapeutics Inc.]( Ticker: [SMMT]( Recent Price: $4.37 Average Analyst Price Target: $8.00 (83.07%) Market Cap: $3.06B Role Transaction Description No. of Shares Amount Date CEO, Director Informative Buy Non Open Market Buy 94,071 $411,094 2 Days Ago CFO Informative Buy Non Open Market Buy 85,812 $375,000 2 Days Ago Recent Analyst Action: Bradley Canino, analyst at Stifel Nicolaus, reiterates coverage on [Summit Therapeutics Inc. (SMMT)]( in the Healthcare sector with a Buy rating and a price target of $8 (2 days ago). Here are 3rd party ratings for [SMMT](: - TipRanks.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 36% (90 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Reddit, Inc.]( Ticker: [RDDT]( Recent Price: $53.48 Average Analyst Price Target: $54.00 (0.97%) Market Cap: $8.50B Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 6,357 $340,000 2 Days Ago Director Informative Buy Non Open Market Buy 1,907 $102,000 2 Days Ago Recent Analyst Action: Daniel Salmon, analyst at New Street, reiterates coverage on [Reddit, Inc. (RDDT)]( in the Communication Services sector with a Hold rating and a price target of $54 (2 days ago). Here are 3rd party ratings for [RDDT](: - TipRanks.com: Hold - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: n/a - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The Presidential candidate your should REALLY be worried about]( Americans are overlooking the seemingly impossible candidate that should worry you. It's not Biden… Trump… Newsom… or even Michelle. It's someone even worse. New evidence of a secret plan indicates he could soon return, and finish what he started. [Get the full story right here.]( --------------------------------------------------------------- [Herbalife Nutrition Ltd.]( Ticker: [HLF]( Recent Price: $9.89 Average Analyst Price Target: $12.50 (26.39%) Market Cap: $981.70M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 15,282 $151,143 2 Days Ago Director Informative Buy Non Open Market Buy 5,067 $50,121 2 Days Ago Recent Analyst Action: Linda Bolton, analyst at D.A. Davidson, reiterates coverage on [Herbalife Nutrition Ltd. (HLF)]( in the Consumer Defensive sector with a Hold rating and a price target of $9.5 (2 days ago). Here are 3rd party ratings for [HLF](: - TipRanks.com: Hold - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Strong Sell, Bottom 8% (232 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Mirum Pharmaceuticals, Inc.]( Ticker: [MIRM]( Recent Price: $25.36 Average Analyst Price Target: $49.40 (94.79%) Market Cap: $1.18B Role Transaction Description No. of Shares Amount Date CFO Informative Buy Non Open Market Buy 1,955 $49,600 2 Days Ago Recent Analyst Action: Mani Foroohar, analyst at Leerink Partners, reiterates coverage on [Mirum Pharmaceuticals, Inc. (MIRM)]( in the Healthcare sector with a Buy rating and a price target of $43 (1 week ago). Here are 3rd party ratings for [MIRM](: - TipRanks.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Top 32% (80 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Big Pharma's Worst Nightmare Could Make You Rich]( tiny firm’s patented “smart cell” technology could turn the drug industry upside down. [Click here now for details.]( --------------------------------------------------------------- [ImmunoPrecise Antibodies Ltd.]( Ticker: [IPA]( Recent Price: $1.59 Average Analyst Price Target: $9.00 (466.04%) Market Cap: $41.84M Role Transaction Description No. of Shares Amount Date Interim Chief Financial Officer Informative Buy Buy 5,000 $7,650 2 Days Ago President & CEO Informative Buy Buy 3,000 $4,470 3 Days Ago Recent Analyst Action: Swayampakula Ramakanth, analyst at H.C. Wainwright, reiterates coverage on [ImmunoPrecise Antibodies Ltd. (IPA)]( in the Healthcare sector with a Buy rating and a price target of $9 (1 week ago). Here are 3rd party ratings for [IPA](: - TipRanks.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Top 34% (86 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Zevia PBC]( Ticker: [ZVIA]( Recent Price: $1.08 Average Analyst Price Target: $3.75 (247.22%) Market Cap: $77.60M Role Transaction Description No. of Shares Amount Date SVP, GC & Corporate Secretary Informative Buy Non Open Market Buy 4,930 $5,325 2 Days Ago Recent Analyst Action: Alton Stump, analyst at Loop Capital Markets, reiterates coverage on [Zevia PBC (ZVIA)]( in the Consumer Defensive sector with a Buy rating and a price target of $4 (1 month ago). Here are 3rd party ratings for [ZVIA](: - TipRanks.com: Hold - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 35% (89 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Make the Chinese Pay Up]( There's a simple, and probably inevitable, way to make several times your money - at the expense of the Chinese Communist Party. This opportunity comes about because China's Central Bank has been buying record amounts of gold. [Here are three ways to front-run the Chinese government - and make them pay more for the gold they want]( - from the comfort of your laptop. --------------------------------------------------------------- And there you have it. To Your Financial Freedom, The Editor MarketSectorDaily.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be third-party advertisements where the advertiser is paying per click, per lead, or per sale and are not endorsed or warranted by our staff or company. SPMG, MarketSectorDaily.com and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged not to use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. SPMG, MarketSectorDaily.com nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from SPMG or MarketSectorDaily.com to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketSectorDaily.com MarketSectorDaily.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Mt. Mourne | North Carolina | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software